Did the FDA Just Put Lorillard Earnings at Risk?
Lorillard will release its quarterly report on Thursday, and until recently, investors had been very optimistic about the company's long-term prospects, bidding the shares up to all-time highs since its 2008 initial public offering. But bad news from the FDA today threatens to put a stop to the growth that Lorillard earnings have seen lately, and shares tumbled as a result.
Lorillard isn't a household name among most consumers, but with cigarette brands like Newport and Kent, most smokers are at least familiar with its products. The tobacco industry in general has had trouble posting solid growth lately, with overall declines in volume as smoking becomes less common in the U.S., but Lorillard has bucked the trend with solid growth in both earnings and revenue. Will the FDA's move reverse the company's fortunes going forward? Let's take an early look at what's been happening with Lorillard over the past quarter and what we're likely to see in its quarterly report.
Stats on Lorillard
Analyst EPS Estimate
Change From Year-Ago EPS
Change From Year-Ago Revenue
Earnings Beats in Past 4 Quarters
Source: Yahoo! Finance.
Where are Lorillard earnings headed this quarter?
Over the past few months, analysts had actually boosted their views on Lorillard earnings, holding their June-quarter estimates steady but adding $0.02 per share to their full-year 2013 calls and a full dime per share for 2014. The stock had also been doing very well, climbing almost 15% since mid-April.
Lorillard's success has come from a combination of strategies aimed at diversifying its overall product portfolio. On one hand, the company has vigorously defended its core cigarette market, joining with peer Reynolds American to defeat an FDA proposal last year that would have greatly expanded requirements for graphic warning labels on cigarette packaging. Even with an onslaught of ad campaigns and more local smoking restrictions, Lorillard has been able to keep growing, with sales up 3.3% in the first quarter compared to the year-ago quarter and climbing market share for its overall cigarette portfolio and for Newport in particular. Lorillard also got FDA approval for new non-menthol cigarettes last month under the Newport brand, with plans to start marketing Non-Menthol Gold Box and Gold Box 100 products in the near future.
Lorillard has also embraced change in the industry, with its blu eCigs available in more than 80,000 retail outlets and posting 40% retail market share in the emerging e-cigarette market. With its alternative method of delivering nicotine to consumers, e-cigarettes could end up escaping the harsh regulation that applies to tobacco products, and Lorillard has gotten in ahead of industry giant Altria and other rivals in identifying the e-cigarette trend and coming up with a strong sales strategy.
But today's preliminary evaluation from the FDA could pose a big problem for Lorillard. The agency asked for input on whether to set new standards that would prohibit or limit the use of menthol in cigarettes, having determined that menthol cigarettes raise public health issues and could encourage smoking. Although both Altria and Reynolds American sell menthol versions of their popular cigarette brands, Newport is the top-selling menthol brand, and so Lorillard took the biggest hit today. Industry experts are hopeful that the FDA will stop short of a full ban, but even less extreme measures could affect the company going forward.
In the Lorillard earnings report, don't expect to see any immediate damage from the FDA evaluation, but pay attention to find out how the company plans to respond. Even though a final decision could be years away, the stakes are extremely high for Lorillard if it wants to protect the industry niche that it has worked so hard to carve out for itself.
The best investing approach is also the simplest: Choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
Click here to add Lorillard to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.
The article Did the FDA Just Put Lorillard Earnings at Risk? originally appeared on Fool.com.Fool contributor Dan Caplinger has no position in any stocks mentioned, and neither does The Motley Fool. You can follow Dan on Twitter @DanCaplinger. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.